Succinyl-CoA-based energy metabolism dysfunction in chronic heart failure.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
11 10 2022
Historique:
entrez: 6 10 2022
pubmed: 7 10 2022
medline: 12 10 2022
Statut: ppublish

Résumé

Heart failure (HF) is a leading cause of death and repeated hospitalizations and often involves cardiac mitochondrial dysfunction. However, the underlying mechanisms largely remain elusive. Here, using a mouse model in which myocardial infarction (MI) was induced by coronary artery ligation, we show the metabolic basis of mitochondrial dysfunction in chronic HF. Four weeks after ligation, MI mice showed a significant decrease in myocardial succinyl-CoA levels, and this decrease impaired the mitochondrial oxidative phosphorylation (OXPHOS) capacity. Heme synthesis and ketolysis, and protein levels of several enzymes consuming succinyl-CoA in these events, were increased in MI mice, while enzymes synthesizing succinyl-CoA from α-ketoglutarate and glutamate were also increased. Furthermore, the ADP-specific subunit of succinyl-CoA synthase was reduced, while its GDP-specific subunit was almost unchanged. Administration of 5-aminolevulinic acid, an intermediate in the pathway from succinyl-CoA to heme synthesis, appreciably restored succinyl-CoA levels and OXPHOS capacity and prevented HF progression in MI mice. Previous reports also suggested the presence of succinyl-CoA metabolism abnormalities in cardiac muscles of HF patients. Our results identified that changes in succinyl-CoA usage in different metabolisms of the mitochondrial energy production system is characteristic to chronic HF, and although similar alterations are known to occur in healthy conditions, such as during strenuous exercise, they may often occur irreversibly in chronic HF leading to a decrease in succinyl-CoA. Consequently, nutritional interventions compensating the succinyl-CoA consumption are expected to be promising strategies to treat HF.

Identifiants

pubmed: 36201541
doi: 10.1073/pnas.2203628119
pmc: PMC9564216
doi:

Substances chimiques

Acyl Coenzyme A 0
Glutamates 0
Ketoglutaric Acids 0
Heme 42VZT0U6YR
Adenosine Diphosphate 61D2G4IYVH
Aminolevulinic Acid 88755TAZ87
succinyl-coenzyme A BSI27HW5EQ

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2203628119

Références

Nat Metab. 2019 Sep 30;1:966-974
pubmed: 32395697
Blood. 2018 Sep 6;132(10):987-998
pubmed: 29991557
J Biol Chem. 2013 Oct 4;288(40):29036-45
pubmed: 23946487
Cell Commun Signal. 2019 Oct 16;17(1):128
pubmed: 31619261
J Am Coll Cardiol. 1996 Sep;28(3):665-72
pubmed: 8772754
Front Cardiovasc Med. 2020 May 12;7:79
pubmed: 32478098
J Physiol. 2017 May 1;595(9):2857-2871
pubmed: 27861911
Cell Rep. 2018 May 29;23(9):2617-2628
pubmed: 29847793
Nature. 2021 Jun;594(7864):560-565
pubmed: 34040253
BMC Genomics. 2018 Nov 12;19(1):812
pubmed: 30419824
J Am Heart Assoc. 2021 Apr 6;10(7):e019667
pubmed: 33787284
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30668551
Nat Commun. 2018 Jan 26;9(1):391
pubmed: 29374152
Nat Rev Cardiol. 2018 Aug;15(8):457-470
pubmed: 29915254
Cardiovasc Res. 2021 Feb 22;117(3):805-819
pubmed: 32402072
Nat Rev Cardiol. 2017 Apr;14(4):238-250
pubmed: 28004807
Nature. 2014 Nov 20;515(7527):431-435
pubmed: 25383517
Neurochem Res. 2019 Oct;44(10):2346-2359
pubmed: 30903449
Cardiovasc Res. 2017 Aug 01;113(10):1173-1185
pubmed: 28498888
Nat Med. 2018 Jun;24(6):802-813
pubmed: 29785027
Am J Physiol Heart Circ Physiol. 2021 Dec 1;321(6):H1056-H1073
pubmed: 34623181
Mol Metab. 2020 Aug;38:100941
pubmed: 32199817
Cell Metab. 2017 Apr 4;25(4):823-837.e8
pubmed: 28380375
Mol Genet Metab. 2019 Nov;128(3):178-189
pubmed: 31345668
EMBO Mol Med. 2016 Feb 19;8(3):247-67
pubmed: 26896449
Cancer Sci. 2021 Jul;112(7):2652-2663
pubmed: 33934440
J Am Coll Cardiol. 2013 May 7;61(18):1884-93
pubmed: 23500306
Nat Rev Cardiol. 2015 Jan;12(1):6-8
pubmed: 25421167
J Mol Cell Cardiol. 2020 Jan;138:304-317
pubmed: 31836543
Circulation. 2016 Feb 23;133(8):698-705
pubmed: 26819376
Circulation. 2018 Oct 30;138(18):2064-2066
pubmed: 30372141
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4320-5
pubmed: 27051063
Commun Biol. 2021 Jan 29;4(1):138
pubmed: 33514783

Auteurs

Shingo Takada (S)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.
Department of Molecular Biology, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.
Department of Lifelong Sport, School of Sports Education, Hokusho University, Ebetsu, 069-8511 Japan.

Satoshi Maekawa (S)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.

Takaaki Furihata (T)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.

Naoya Kakutani (N)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.

Daiki Setoyama (D)

Department of Clinical Chemistry and Laboratory Medicine, Kyushu University, Fukuoka, 812-8582 Japan.

Koji Ueda (K)

Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, 135-8550 Japan.

Hideo Nambu (H)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.

Hikaru Hagiwara (H)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.

Haruka Handa (H)

Department of Molecular Biology, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.

Yoshizuki Fumoto (Y)

Department of Molecular Biology, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.

Soichiro Hata (S)

Department of Molecular Biology, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.

Tomoka Masunaga (T)

Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan.

Arata Fukushima (A)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.

Takashi Yokota (T)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.

Dongchon Kang (D)

Department of Clinical Chemistry and Laboratory Medicine, Kyushu University, Fukuoka, 812-8582 Japan.
Clinical Laboratories, Kyushu University Hospital, Fukuoka, 812-8582 Japan.

Shintaro Kinugawa (S)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.
Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan.
Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan.

Hisataka Sabe (H)

Department of Molecular Biology, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.
Institute for Genetic Medicine, Hokkaido University, Sapporo, 060-8638 Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH